An investigation of the differential therapeutic effects of romosozumab on postmenopausal osteoporosis patients with or without rheumatoid arthritis complications: a case–control study

Ebina, Kosuke; Nagayama, Yoshio; Kashii, Masafumi; Tsuboi, Hideki; Okamura, Gensuke; Miyama, Akira; Etani, Yuki; Noguchi, Takaaki; Hirao, Makoto; Miura, Taihei; Fukuda, Yuji; Kurihara, Takuya; Nakata, Ken; Okada, Seiji

doi:https://doi.org/10.1007/s00198-024-07019-2

An investigation of the differential therapeutic effects of romosozumab on postmenopausal osteoporosis patients with or without rheumatoid arthritis complications: a case–control study

Ebina, Kosuke; Nagayama, Yoshio; Kashii, Masafumi et al.

Osteoporosis International, 2024, 35, 841-849

Number of Access:1,470（2025-07-24 02:34 Counts）

Identifier to cite or link to this item: https://hdl.handle.net/11094/94642

Link to primary information

File	Format	Terms of use	Size	Views	Date.Available	Description	information
OsteoporosisInt_00198-024-07019-2	pdf	None	970 KB	61	2024.03.13

Creative Commons : Attribution - NonCommercial

Item Information

Output File Export EndNote Basic Export Mendeley

Title	An investigation of the differential therapeutic effects of romosozumab on postmenopausal osteoporosis patients with or without rheumatoid arthritis complications: a case–control study
Creator	NRID 1000070612076 1000070612076 researchmap permalink k-ebina k-ebina Scopus Author ID 8415453300 8415453300 ORCID 0000-0002-2426-1024 0000-0002-2426-1024 CreatorName Ebina, Kosuke
	CreatorName Nagayama, Yoshio
	NRID 1000000576910 1000000576910 CreatorName Kashii, Masafumi
	CreatorName Tsuboi, Hideki
	CreatorName Okamura, Gensuke
	CreatorName Miyama, Akira
	NRID 1000060898930 1000060898930 ORCID 0000-0001-5741-5969 0000-0001-5741-5969 researchmap permalink Yetani0302 Yetani0302 CreatorName Etani, Yuki
	NRID 1000050812294 1000050812294 researchmap permalink takaakinoguchi takaakinoguchi ORCID 0000-0001-9938-6780 0000-0001-9938-6780 CreatorName Noguchi, Takaaki
	NRID 1000010527708 1000010527708 CreatorName Hirao, Makoto
	CreatorName Miura, Taihei
	CreatorName Fukuda, Yuji
	CreatorName Kurihara, Takuya
	NRID 1000000283747 1000000283747 researchmap permalink ken-nakata ken-nakata Scopus Author ID 7402151308 7402151308 CreatorName Nakata, Ken
	NRID 1000030448435 1000030448435 ORCID 0000-0002-5107-8209 0000-0002-5107-8209 researchmap permalink okadaseiji okadaseiji Scopus Author ID 35079139100 35079139100 CreatorName Okada, Seiji
Subject	Bone mineral density
	Postmenopausal osteoporosis
	Rheumatoid arthritis
	Romosozumab
Description	The version of record of this article, first published in Osteoporosis International, is available online at Publisher’s website: https://doi.org/10.1007/s00198-024-07019-2
Abstract	Summary: The impact of ROMO on the width of anabolic windows and the increase in BMD was reduced in the RA group compared to the non-RA group, and this reduction was associated with correlations to RA-related factors. Purpose: To investigate the effects of romosozumab (ROMO) in postmenopausal osteoporosis, with and without comorbid rheumatoid arthritis (RA). Methods: In this retrospective, case-controlled, multicenter study, 171 postmenopausal patients who did not receive oral glucocorticoid, comprising 59 in the RA group and 121 in the non-RA group, received uninterrupted ROMO treatment for 12 months. Propensity score matching was employed to ensure comparability in clinical backgrounds, resulting in 41 patients in each group. Baseline characteristics were as follows: overall (mean age, 76.3 years; T-score of lumbar spine (LS), − 3.0; 45.1% were treatment-naive for osteoporosis); RA group (anti-cyclic citrullinated peptide antibody (ACPA) positivity, 80.5%; titer, 206.2 U/ml; clinical disease activity index (CDAI), 13.6; health assessment questionnaire disability index (HAQ-DI), 0.9). Bone mineral density (BMD) and serum bone turnover markers were monitored over a 12-month period. Results: The rate of increase in the bone formation marker, PINP, and the rates of decrease in the bone resorption marker, TRACP-5b, exhibited a trend toward smaller changes in the RA group compared to the non-RA group, implying a smaller anabolic window. After 12 months, the RA group displayed lower BMD increases in the LS (9.1% vs. 12.6%; P = 0.013) and total hip (2.4% vs. 4.8%; P = 0.025) compared to the non-RA group. Multiple regression analysis in the all RA group (n = 59) for the association between RA-specific factors and 12-month BMD changes revealed negative correlations between ACPA titer and LS BMD and between HAQ-DI and femoral neck BMD. Conclusions: The efficacy of ROMO may be attenuated by RA-related factors.
Publisher	Springer Nature
Source Title	Osteoporosis International
Volume (Issue)	35
Page	841-849
Date of Issued	2024-01-31
Language	English
Handle URL	https://hdl.handle.net/11094/94642
PISSN	0937941X
eISSN	14332965
Relation
Relation.isIdenticalTo	DOI (Publisher Version) https://doi.org/10.1007/s00198-024-07019-2
Access Rights	open access
CopyRight	This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
oaire:version	Version of Record
Category	学術雑誌論文 Journal Article

Resource Type	journal article
Local Type	Journal Article
DCMI Type	Text
DCTERMS.bibliographicCitation	Osteoporosis International. 2024, 35, p. 841-849
DC.title	An investigation of the differential therapeutic effects of romosozumab on postmenopausal osteoporosis patients with or without rheumatoid arthritis complications: a case–control study
DC.creator	Ebina, Kosuke
	Nagayama, Yoshio
	Kashii, Masafumi
	Tsuboi, Hideki
	Okamura, Gensuke
	Miyama, Akira
	Etani, Yuki
	Noguchi, Takaaki
	Hirao, Makoto
	Miura, Taihei
	Fukuda, Yuji
	Kurihara, Takuya
	Nakata, Ken
	Okada, Seiji
DC.publisher	Springer Nature
DC.language' scheme='DCTERMS.RFC1766	English
DC.type' scheme='DCTERMS.DCMIType	Text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2024-01-31
DC.identifier	https://doi.org/10.1007/s00198-024-07019-2
DC.subject	Bone mineral density
	Postmenopausal osteoporosis
	Rheumatoid arthritis
	Romosozumab
DC.description	The version of record of this article, first published in Osteoporosis International, is available online at Publisher’s website: https://doi.org/10.1007/s00198-024-07019-2
DCTERMS.abstract	Summary: The impact of ROMO on the width of anabolic windows and the increase in BMD was reduced in the RA group compared to the non-RA group, and this reduction was associated with correlations to RA-related factors. Purpose: To investigate the effects of romosozumab (ROMO) in postmenopausal osteoporosis, with and without comorbid rheumatoid arthritis (RA). Methods: In this retrospective, case-controlled, multicenter study, 171 postmenopausal patients who did not receive oral glucocorticoid, comprising 59 in the RA group and 121 in the non-RA group, received uninterrupted ROMO treatment for 12 months. Propensity score matching was employed to ensure comparability in clinical backgrounds, resulting in 41 patients in each group. Baseline characteristics were as follows: overall (mean age, 76.3 years; T-score of lumbar spine (LS), − 3.0; 45.1% were treatment-naive for osteoporosis); RA group (anti-cyclic citrullinated peptide antibody (ACPA) positivity, 80.5%; titer, 206.2 U/ml; clinical disease activity index (CDAI), 13.6; health assessment questionnaire disability index (HAQ-DI), 0.9). Bone mineral density (BMD) and serum bone turnover markers were monitored over a 12-month period. Results: The rate of increase in the bone formation marker, PINP, and the rates of decrease in the bone resorption marker, TRACP-5b, exhibited a trend toward smaller changes in the RA group compared to the non-RA group, implying a smaller anabolic window. After 12 months, the RA group displayed lower BMD increases in the LS (9.1% vs. 12.6%; P = 0.013) and total hip (2.4% vs. 4.8%; P = 0.025) compared to the non-RA group. Multiple regression analysis in the all RA group (n = 59) for the association between RA-specific factors and 12-month BMD changes revealed negative correlations between ACPA titer and LS BMD and between HAQ-DI and femoral neck BMD. Conclusions: The efficacy of ROMO may be attenuated by RA-related factors.
DC.rights	This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
DC.format	94642
citation_title	An investigation of the differential therapeutic effects of romosozumab on postmenopausal osteoporosis patients with or without rheumatoid arthritis complications: a case–control study
citation_author	Ebina, Kosuke
	Nagayama, Yoshio
	Kashii, Masafumi
	Tsuboi, Hideki
	Okamura, Gensuke
	Miyama, Akira
	Etani, Yuki
	Noguchi, Takaaki
	Hirao, Makoto
	Miura, Taihei
	Fukuda, Yuji
	Kurihara, Takuya
	Nakata, Ken
	Okada, Seiji
citation_publisher	Springer Nature
citation_language	English
citation_date	2024-01-31
citation_journal_title	Osteoporosis International
citation_volume	35
citation_firstpage	841
citation_lastpage	849
citation_doi	https://doi.org/10.1007/s00198-024-07019-2
citation_public_url	https://hdl.handle.net/11094/94642

An investigation of the differential therapeutic effects of romosozumab on postmenopausal osteoporosis patients with or without rheumatoid arthritis complications: a case–control study

Link to primary information

Item Information

Show details